Neuland's Saharsh Davuluri checks in on Chinese out-licensing, peptide capacity, and CDMO agility six months after his December 2025 predictions.
Saharsh Davuluri
Advertisement
CEO & Managing Director
Neuland Laboratories
Articles by Saharsh Davuluri
Neuland's Saharsh Davuluri revisits his December predictions for 2026, reporting steady progress on India manufacturing and AI adoption at midyear.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data
2
Everything to Know about BMS & NVidia’s AI Supercomputer
3
Brent Wilhelm on Cold Chain Pharmaceuticals Reshaping Shipping Needs
4
Can AI Fix Pharma's Last-Mile Delivery Blind Spot?
5